GLP-1 side effects on TikTok: what's real vs. overdramatised
Quick answer
The transcript captures a patient on a GLP-1 receptor agonist experiencing ongoing hunger, which is clinically consistent with how these medications work at various dose stages. GLP-1 drugs reduce but do not universally eliminate appetite, and side effect profiles, particularly gastrointestinal symptoms, are well-documented in the clinical literature. Patients should report persistent or distressing symptoms to their prescriber rather than self-managing based on social media accounts.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @freyas.journey20 actually say?
Not much, honestly. The transcript here is thin: "You're not sick. No, no, in fact. Helen, I'm hungry and I wish I had a snack." That's the whole thing. The caption promises transparency about GLP-1 side effects, which the creator describes as "not fun," but the spoken content captured here doesn't actually explain what those side effects are. What comes through clearly is that hunger is still present, which runs counter to a common public assumption about GLP-1 medications.
To be fair to the creator, TikTok videos often carry meaning through visuals, tone, and context that a transcript alone can't capture. The caption framing suggests this is a personal experience video, not a medical advice video, which is appropriate territory for a patient sharing their journey.
Does the science back this up?
The implicit claim here, that GLP-1 medications don't eliminate hunger entirely, is actually well-supported. GLP-1 receptor agonists reduce appetite through several mechanisms, including slowing gastric emptying and acting on hypothalamic satiety centers, but they do not switch hunger off like a light switch for everyone.
Wilding et al. (2021, New England Journal of Medicine), the landmark semaglutide trial, showed significant weight loss in participants, but also documented that a meaningful proportion reported nausea, vomiting, and gastrointestinal distress as the most common side effects, not complete appetite suppression. Hunger can persist, particularly between dose escalations or at lower doses. Jastreboff et al. (2022, New England Journal of Medicine) found similar patterns with tirzepatide. The lived experience of still feeling hungry while on a GLP-1 medication is real and documented, not a sign the medication is failing.
What did they get wrong (or right)?
There isn't enough spoken content here to identify a factual error. The creator didn't make a clinical claim, didn't recommend a dose, and didn't oversell the medication. Saying "I'm hungry and I wish I had a snack" while on a GLP-1 is an honest, accurate reflection of how these medications actually work for many people.
What the creator got right, even implicitly, is pushing back on the popular narrative that GLP-1 drugs are a effortless cure that removes all desire to eat. That myth has real consequences. Patients who expect complete appetite elimination may interpret ongoing hunger as treatment failure and either increase their dose unsafely or abandon treatment. The creator's willingness to show the less glamorous side of the experience is genuinely useful public health communication, even if the transcript itself is fragmentary.
One caveat: the caption mentions side effects are "not fun" without specifying what they are. GLP-1 side effects vary considerably and some, like severe nausea or gastroparesis in rare cases, warrant clinical attention. Personal experience videos are valuable but shouldn't substitute for speaking with a prescriber about specific symptoms.
What should you actually know?
GLP-1 receptor agonists work differently from person to person. Nausea and gastrointestinal symptoms are the most commonly reported side effects, particularly during dose escalation. Hunger reduction is real for most patients, but it is rarely total, and it tends to be more pronounced at higher doses.
If you're on a GLP-1 medication and still feeling hungry, that does not mean the medication isn't working. Weight loss on these drugs typically occurs over months, not weeks, and appetite changes can lag behind dose increases. Davies et al. (2021, Diabetes Care) noted that individual response variability is significant across GLP-1 therapies. Tracking symptoms and reporting them to your prescriber is more useful than adjusting expectations based on social media content, even well-intentioned content like this video. A telehealth provider can help distinguish normal adjustment-phase symptoms from side effects that need managing.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 side effects on TikTok: what's real vs. overdramatised, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 side effects on TikTok: what's real vs. overdramatised is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The transcript captures a patient on a GLP-1 receptor agonist experiencing ongoing hunger, which is clinically consistent with how these medications work at various dose stages.
FormBlends verdict
The transcript captures a patient on a GLP-1 receptor agonist experiencing ongoing hunger, which is clinically consistent with how these medications work at various dose stages. GLP-1 drugs reduce but do not universally eliminate appetite, and side effect profiles, particularly gastrointestinal symptoms, are well-documented in the clinical literature. Patients should report persistent or distressing symptoms to their prescriber rather than self-managing based on social media accounts.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The transcript captures a patient on a GLP-1 receptor agonist experiencing ongoing hunger, which is clinically consistent with how these medications work at various dose stages. GLP-1 drugs reduce but do not universally eliminate appetite, and side effect profiles, particularly gastrointestinal symptoms, are well-documented in the clinical literature. Patients should report persistent or distressing symptoms to their prescriber rather than self-managing based on social media accounts.
- Wilding et al. (2021, NEJM) found nausea and vomiting were the most common side effects leading to discontinuation in the semaglutide STEP trials, affecting roughly 10-15% of participants.
- GLP-1 receptor agonists slow gastric emptying and act on hypothalamic appetite centers, but hunger reduction is partial and variable, not total, for most patients.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Wilding et al. (2021, NEJM) found nausea and vomiting were the most common side effects leading to discontinuation in the semaglutide STEP trials, affecting roughly 10-15% of participants.
- GLP-1 receptor agonists slow gastric emptying and act on hypothalamic appetite centers, but hunger reduction is partial and variable, not total, for most patients.
- Jastreboff et al. (2022, NEJM) showed tirzepatide produced up to 22.5% body weight reduction on average, but individual responses varied considerably across the trial population.
- Ongoing hunger during GLP-1 treatment is not evidence of treatment failure. Appetite effects often become more pronounced as doses are escalated over weeks to months.
- Davies et al. (2021, Diabetes Care) noted that patient experience with GLP-1 therapies differs significantly based on dose, duration, and individual metabolic factors.
- Side effect experiences shared on social media can be useful for normalizing patient experiences but should not replace clinical guidance on managing specific symptoms.
- Patients experiencing distressing side effects on GLP-1 medications should contact their prescriber rather than adjusting medication use based on peer accounts online.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Freyas.Journey20 · TikTok creator
79.5K views on this video
The side effects are not fun 😭!! This isn’t to put anyone off having it however I plan on being totally transparent with my journey!
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Freyas.Journey20, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.